Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice - Concepedia

Concepedia

Publication | Open Access

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

DOI Full Paper Access

141

Citations

48

References

2016

Year

Linda A. Gallo, Micheal Ward, Amelia K. Fotheringham, Aowen Zhuang, Danielle J. Borg, Nicole Flemming, Ben M. Harvie, Toni L. Kinneally, Shang-Ming Yeh, Domenica A. McCarthy,

Scientific Reports

References

	Year	Citations

Page 1